Bariatric surgery may help reduce the rates of vaso-occlusive crises (VOCs) in morbidly obese patients with sickle cell disease (SCD) without increasing the risk of mortality or other adverse events, a study says.
“For many years, SCD was stereotypically represented by an undernourished child with delayed growth and poor immunologic function. However, there has been a significant improvement in the
management of SCD patients over the past few decades. Early diagnosis coupled with introduction of disease-modifying therapy has significantly improved life expectancy of SCD patients. With increased longevity, SCD patients are susceptible to developing chronic medical problems such as obesity,” the researchers said.
In this study, a group of investigators from the Yale University School of Medicine and collaborators set out to assess the impact of weight-loss (bariatric) surgery on the clinical outcomes of morbidly obese patients with SCD. Bariatric surgery reduces the amount of food the stomach can hold, causing weight loss.
Patients were selected based on hospital discharge records stored at the United States Nationwide Inpatient Sample database containing the co-diagnosis of morbid obesity and SCD.
The study’s primary outcome was to evaluate patients’ in-hospital mortality rates. Secondary outcomes included the frequency of VOCs, acute chest syndrome (ACS), liver and pancreas complications, kidney and respiratory failure and other adverse events, hospitalization length and costs.
From the 2,549 patients with a discharge diagnosis of SCD and morbid obesity found in the database between 2004 and 2014, 42 (1.7%) underwent weight-loss surgery.
Further analysis demonstrated that patients who underwent the surgery did not have a higher risk of mortality, or of developing other medical complications, including ACS, sepsis, and multi-organ failure. They were less likely to experience VOCs compared to those who did not have the surgery.
The significant reduction in the risk of VOCs in these patients was associated with a shorter period of hospitalization, but also with higher hospitalization costs.
“Our study suggests that bariatric surgery may reduce the rates of vaso-occlusive crises in obese patients with SCD. In addition, there was no significant difference in in-hospital mortality or other major complications between SCD patients who underwent bariatric surgery and those who did not,” the investigators said.
“We are hopeful that our results will motivate physicians to consider bariatric surgery as a safe and effective treatment option for SCD patients with morbid obesity. Although the results of this
study are narrowed based upon database and study design limitations, we hope our study encourages future exploration on the subject of sickle cell disease and bariatric surgery. Prospective studies, although difficult to design given the incidence of bariatric surgery and sickle cell disease, are needed to validate our findings,” they said.